Amgen Inc (NASDAQ: AMGN) has reported E.P.S. of $-0.21 for its first fiscal quarter (ending March 31) versus $5.32 for the same period a year ago — a decline of -104%. Relative to the consensus estimate of $5.19, this was a shortfall of $-5.40. For the latest four quarters through March 31, E.P.S. were $7.03 compared to $14.81 a year ago — a decline of -53%.
Recent Price Action
Amgen Inc (NASDAQ: AMGN) stock rose modestly by 0.4% on 5/2/24. The stock closed at $278.39. This advance was accompanied by normal trading volume. The stock has performed in line with the market over the last nine months and has risen 2.0% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, AMGN is expected to continue to be a major Value Builder.
Amgen has a current Value Trend Rating of B (Positive). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Amgen has a neutral Power Rating of 54 but a very high Appreciation Score of 87, resulting in the Positive Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment